Dental implant in a multiple myeloma patient undergoing bisphosphonate therapy: A case report

Bayani, Mojtaba; Anooshirvani, Ali Arash; Keivan, Mohammad; Mohammad-Rabei, Elham

doi:10.1002/ccr3.2150

Cited by 2 publications

(8 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 42 patients (63%) were on therapy with BPs administered orally, and 25 patients (37%) received BPs through IV. For oral administration, the drugs were Alendronate [14][15][16][17][18][19][20][21], Risedronate [16,17,21], and Ibandronate [14,17,19], whereas those administered intravenously were Zoledronate [14,17,19,[22][23][24][25][26], Clodronate [27], and Pamidronate [14,19,26]. The duration of the use of BPs at the time of implant placement was diverse.…”

Section: Resultsmentioning

confidence: 99%

“…Of all the studies included, the presence of patients undergoing therapy with second generation (Alendronate, Pamidronate) [14][15][16][17][18][19][20]25] and third generation BPs (Risedronate, Zoledronate and Ibandronate) [14,16,17,19,[21][22][23][24][25] were greater than the use of first generation (Clodronate) [26]. The first generation seems to show a decreasing trend in use nowadays.…”

Section: Bp Use and Dental Implantsmentioning

confidence: 99%

“…There was no bone loss around both implants, and it was observed that the peri-implant soft tissue did not show any signs of inflammation. Bayani et al [21] reported that the placement of dental implants in patients with MM undergoing therapy with third generation BPs (Zoledronate) can be performed. Therefore, a meticulous selection of cases, an adequate medical consultation, and a minimally invasive surgery should be considered.…”

Section: Bp Use and Dental Implantsmentioning

confidence: 99%

“…Otherwise, Bayani et al [21] reported the discontinuation of BP therapy for6 months before surgery that was resumed therapy 8 months after surgery. The failure rate was 0%, and no complications were observed.…”

Section: Bp Use and Dental Implantsmentioning

confidence: 99%

“…Specifically, for four studies without implant failure [15,16,21,23], all cases reported types of study that must be carefully interpreted, due to the low level of scientific weight, Bayani et al [21] found excellent results after a 1-year follow up in a 54-year-old man patient with multiple myeloma (MM) who complained of difficulty in mastication and esthetical concern for his upper anterior teeth. He received a monthly infusion of 3.5 mg of the IV BP drug Zoledronate for a period of 22 months, which is considered a long period and a high-risk treatment.…”

Section: Bp Use and Dental Implantsmentioning

confidence: 99%

See 4 more Smart Citations

Bisphosphonates and Their Influence on the Implant Failure: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Objective: The goal of this systematic review was to study the relationship between the use of bisphosphonates (oral or intravenous) and its effect on implant osseointegration. Methods: The focused question was “In patients medicated with bisphosphonates and who underwent surgery to place dental implants, what is the influence of that medication (of different generations) on the failure of dental implants (O)?” Following specific eligibility criteria, four databases (PubMed/MEDLINE, Scopus, Web of Science, DOAJ) were electronically screened to search the articles. Specific MeSH terms were used in combinations with Boolean Operators “AND” and “OR” for the research. In addition, a manual search was done. The data extracted were the (i) author, (ii) year of publication, (iii) country, (iv) research question, (v) study design, (vi) patient information, (vii) the number of patients included, (viii) patient/implant status, (ix) the number of implants evaluated, (x) type of implant, (xi) risk factors, and (xii) findings obtained. Moreover, the following were also registered: the (i) type, generation, duration, and route for BP administrated; (ii) the presence of any systemic condition and drug treatment; (iii) follow-up (months); and (iv) implant failure rate (%). The quality assessment of the included studies was carried out using the Modified Newcastle–Ottawa scale. Results: A total of 491 articles were found (183 in PubMed/MEDLINE, 171 in Scopus, 65 in Web of Science, and 72 articles in DOAJ), and 17 articles were considered for full-text reading. After the exclusion of 3 articles, 14 were included in this systematic review (11 case reports, 2 retrospective, and 1 prospective study). The reasons for the bisphosphonates intaking included osteoporosis, multiple myeloma, breast cancer, knee cancer, and osteogenesis imperfecta. The oral administration involved Alendronato (eight studies), Risedronate (three studies), and Ibandronate (three studies); whereas the intravenous administrations were Zoledronate (seven studies), Clodronato (one study), and Pamidronato (three studies). The duration of use of bisphosphonates at the time of implant placement was diverse; it ranged from no interruption of bisphosphonate intaking up to its discontinuation for 2, 3, or 6 months before surgery, with respective use being resumed 1, 3, or 8 months after surgery. Antibiotic treatment (amoxicillin + clavulanic acid) was performed before the intervention in two cases and after the intervention in three cases. Finally, the percent of implant failure rate when intaking BPs had an average of 49.96%. Conclusions: Within the limitation of this systematic review, it was possible to conclude that a high mean failure rate of implant osseointegration (49.96%) was found, regardless of the generation of bisphosphonates used. Moreover, the failure rate was lower in patients using second generation bisphosphonates (Alendronate and Pamidronate) and was higher with the IV administration compared to the oral administration of bisphosphonates.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Bp Use and Dental Implantsmentioning

confidence: 99%

Section: Bp Use and Dental Implantsmentioning

confidence: 99%

Section: Bp Use and Dental Implantsmentioning

confidence: 99%

Section: Bp Use and Dental Implantsmentioning

confidence: 99%

See 3 more Smart Citations

Bisphosphonates and Their Influence on the Implant Failure: A Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

Dental implant considerations in patients with systemic diseases: An updated comprehensive review

Mosaddad,

Talebi,

Keyhan

et al. 2024

J of Oral Rehabilitation

View full text Add to dashboard Cite

BackgroundVarious medical conditions and the drugs used to treat them have been shown to impede or complicate dental implant surgery. It is crucial to carefully monitor the medical status and potential post‐operative complications of patients with systemic diseases, particularly elderly patients, to minimize the risk of health complications that may arise.AimThe purpose of this study was to review the existing evidence on the viability of dental implants in patients with systemic diseases and to provide practical recommendations to achieve the best possible results in the corresponding patient population.MethodsThe information for our study was compiled using data from PubMed, Scopus, Web of Science and Google Scholar databases and searched separately for each systemic disease included in our work until October 2023. An additional manual search was also performed to increase the search sensitivity. Only English‐language publications were included and assessed according to titles, abstracts and full texts.ResultsIn total, 6784 studies were found. After checking for duplicates and full‐text availability, screening for the inclusion criteria and manually searching reference lists, 570 articles remained to be considered in this study.ConclusionIn treating patients with systemic conditions, the cost–benefit analysis should consider the patient's quality of life and expected lifespan. The success of dental implants depends heavily on ensuring appropriate maintenance therapy, ideal oral hygiene standards, no smoking and avoiding other risk factors. Indications and contraindications for dental implants in cases of systemic diseases are yet to be more understood; broader and hardcore research needs to be done for a guideline foundation.

show abstract

Dental implant in a multiple myeloma patient undergoing bisphosphonate therapy: A case report

Cited by 2 publications

References 23 publications

Bisphosphonates and Their Influence on the Implant Failure: A Systematic Review

Bisphosphonates and Their Influence on the Implant Failure: A Systematic Review

Dental implant considerations in patients with systemic diseases: An updated comprehensive review

Contact Info

Product

Resources

About